tbuckley/cabot-search huggingface dataset:
604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
Authors: S. Leyvraz, J.C-H. Yang, P.G. Casali, G. Castro, E.S. Kim, U.N. Lassen, F. Lopez-Rios, F. Penault-Llorca, A. Pappo, E.R. Rudzinski, G. Tabatabai, G. Vassal, J.A. Reeves, H. Nogai, M. Fellous, A. Drilon, M.S. Brose, J. Trent
Journal: Annals of Oncology (2020)
LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas
Authors: M. Toulmonde, M. Brahmi, A. Giraud, A. Bessede, M. Kind, E. Toulza, M. Pulido, S. Cousin, K. Bourcier, S. Albert, S. Mothes, C. Chakiba, I.L. Ray-Coquard, A. Floquet, S. Croce, S. Mathoulin-Pélissier, R. Perret, J-Y. Blay, A. Italiano
Journal: Annals of Oncology (2020)
LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
Authors: I-M. Svane, J.W. Kjeldsen, C.L. Lorentzen, E. Martinenaite, M.H. Andersen
Journal: Annals of Oncology (2020)
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
Authors: Yuchen Liu, Xiaohui Wang, Yingzi Yang
Journal: Clinical and Molecular Hepatology (2020)

Primary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte proliferation, survival, and HCC formation. A key component of the Hippo pathway is the inhibition of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) transcription factors by the Hippo kinase cascade. Aberrant activation of YAP or TAZ has been found in several human cancers including HCC. It is also well established that YAP/TAZ activation in hepatocytes causes HCC in mouse models, indicating that YAP/TAZ are potential therapeutic targets for human liver cancer. In this review, we summarize the recent findings regarding the multifarious roles of Hippo/YAP/TAZ in HCC development, and focus on their cell autonomous roles in controlling hepatocyte proliferation, differentiation, survival and metabolism as well as their non-cell autonomous in shaping the tumor microenvironment.
1485P Response prediction using NanoString nCounter technology and NGS panel sequencing in neoadjuvant chemotherapy in patients with esophagogastric adenocarcinoma
Authors: S.K.F. Daum, C. Treese, A. Arnold, H. Harloff, H. Lammert, F. Mairinger, M. Hummel, K. Kleo
Journal: Annals of Oncology (2020)
887MO Real-world treatment management of patients with advanced-stage classic Hodgkin lymphoma receiving front line therapy
Authors: A. Avigdor, F. Trinchese, F. Gavini, N. Bent-Ennakhil, M. Dalal, A. Zomas, S. Gettner Broun, G. Gini
Journal: Annals of Oncology (2020)
1628MO A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Authors: G. Kantidakis, S. Litiere, A. Neven, M. Vinches, I. Judson, P. Schöffski, S. Stacchiotti, L. D’Ambrosio, S.I. Marreaud, W.T.A. Van Der Graaf, M. Fiocco, B. Kasper, H. Gelderblom
Journal: Annals of Oncology (2020)
1560P Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Prevalence and clinical implications
Authors: I. Trestini, S. Paiella, M. Sandini, T. Hank, T. Pollini, I. Sperduti, D. Melisi, A. Auriemma, C. Soldà, D. Tregnago, A. Avancini, G. Malleo, M. D'Onofrio, L. Gianotti, S. Pilotto, R. Salvia, C.F. del Castillo, C. Bassi, M. Milella
Journal: Annals of Oncology (2020)
enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9
Authors: Jasper Edgar Neggers, Maarten Jacquemyn, Tim Dierckx, Benjamin Peter Kleinstiver, Hendrik Jan Thibaut, Dirk Daelemans
Journal: Molecular Therapy (2020)

While drug resistance mutations provide the gold standard proof for drug target engagement, target deconvolution of inhibitors identified from a phenotypic screen remains challenging. Genetic screening for functional in-frame drug resistance mutations by tiling CRISPR-Cas nucleases across protein coding sequences is a method for identifying a drug's target and binding site. However, the applicability of this approach is constrained by the availability of nuclease target sites across genetic regions that mediate drug resistance upon mutation. In this study, we show that an enhanced AsCas12a variant (enAsCas12a), which harbors an expanded targeting range, facilitates screening for drug resistance mutations with increased activity and resolution in regions that are not accessible to other CRISPR nucleases, including the prototypical SpCas9. Utilizing enAsCas12a, we uncover new drug resistance mutations against inhibitors of NAMPT and KIF11. These findings demonstrate that enAsCas12a is a promising new addition to the CRISPR screening toolbox and allows targeting sites not readily accessible to SpCas9.
1812MO Effects of oncologic rehabilitation during adjuvant endocrine therapy in overweight or obese patients with breast cancer
Authors: H.L. Ormel, C.P. Schröder, G.G.F. Van der Schoot, A. Van der Velden, B.J. Poppema, A.K.L. Reyners, A.M.E. Walenkamp
Journal: Annals of Oncology (2020)
847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands
Authors: L. Van Wagensveld, O. Colomban, M. Van Der AA, M. Tod, G.S. Sonke, R. Kruitwagen, B. You
Journal: Annals of Oncology (2020)
Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis
Authors: Gabriel Westman, Elisabeth Aurelius, Clas Ahlm, Kaj Blennow, Kristina Eriksson, Liza Lind, Silvia Schliamser, Fredrik Sund, Henrik Zetterberg, Marie Studahl
Journal: Clinical Microbiology and Infection (2020)

ObjectivesThe aim was to investigate the correlation between biomarkers of brain injury and long-term neurocognitive outcome, and the interplay with intrathecal inflammation and neuronal autoimmunity, in patients with herpes simplex encephalitis (HSE).MethodsA total of 53 adult/adolescent HSE patients were included from a prospective cohort in a randomized placebo-controlled trial investigating the effect of a 3-month follow-up treatment with valaciclovir. Study subjects underwent repeated serum/cerebrospinal fluid (CSF) sampling and brain magnetic resonance imaging in the first 3 months along with cognitive assessment using the Mattis Dementia Rating Scale (MDRS) at 24 months. CSF samples were analysed for biomarkers of brain injury, inflammation and synaptic autoimmunity. The predefined primary analysis was the correlation between peak CSF neurofilament protein (NFL), a biomarker of neuronal damage, and MDRS at 24 months.ResultsImpaired cognitive performance significantly correlated with NFL levels (rho = –0.36, p = 0.020). Development of IgG anti-N-methyl-D-aspartate receptor (NDMAR) antibodies was associated with a broad and prolonged proinflammatory CSF response. In a linear regression model, lower MDRS at 24 months was associated with previous development of IgG anti-N-methyl-D-aspartate receptor (NMDAR) (beta = –0.6249, p = 0.024) and age (z-score beta = –0.2784, p = 0.024), but not CSF NFL, which however significantly correlated with subsequent NMDAR autoimmunization (p = 0.006).DiscussionOur findings show that NFL levels are predictive of long-term neurocognitive outcome in HSE, and suggest a causative chain of events where brain tissue damage increases the risk of NMDAR autoimmunisation and subsequent prolongation of CSF inflammation. The data provides guidance for a future intervention study of immunosuppressive therapy administered in the recovery phase of HSE.
EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib
Authors: Niamh Coleman, David Woolf, Liam Welsh, Fiona McDonald, Suzanne MacMahon, Nadia Yousaf, Sanjay Popat
Journal: Journal of Thoracic Oncology (2020)
976TiP SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer
Authors: E.E. Cohen, L. Dunn, P. Neupane, M. Gibson, R. Leidner, P. Savvides, N. Hyland, T. Trivedi, M. Dudley, S. Biswas, D. Williams, E. Norry
Journal: Annals of Oncology (2020)
LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Authors: P.A. Ascierto, M. Mandala, P.F. Ferrucci, P. Rutkowski, M. Guidoboni, A.M. Arance Fernandez, V. Ferraresi, E. Maiello, M. Guida, M. Del Vecchio, M.T. Fierro, P. Queirolo, C. Lebbé, H. Helgadottir, I. Melero, G. Palmieri, D. Giannarelli, A.M. Grimaldi, R. Dummer, V. Chiarion Sileni
Journal: Annals of Oncology (2020)
Reflections of a Black woman physician-scientist
Authors: Rotonya M. Carr
Journal: Journal of Clinical Investigation (2020)

order=0 lang=eng>Black women comprise 1 6% of clinical and nonclinical faculty at academic medical centers compared with 22 9% for White women  Consequently, Black women physician-scientists are more likely than not to be an underrepresented demographic among our colleagues  Here, Carr shares her experience as a Black women physician-scientists
Mutations make gut antibodies promiscuous
Authors: Emilie K. Grasset, Andrea Cerutti
Journal: The Journal of Experimental Medicine (2020)

In this issue, Kabbert et al. (https://doi.org/10.1084/jem.20200275) show that intestinal antibodies from healthy subjects or patients with Crohn’s disease cross-target diverse but distinct communities of the gut microbiota through a mechanism involving somatic hypermutation but not germline-encoded polyreactivity.
1596P Could population-based cancer registries contribute to breast cancer screening assessment?
Authors: M.D.C. Martos, F. Giusti, L. Neamtiu, G. Randi, T.A. Dyba, M. Flego, N. Dimitrova, R. Carvalho, N. Nicholson, M. Bettio
Journal: Annals of Oncology (2020)
224P Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study
Authors: Z. Liu, J. Zhu, C. Wang, X. Sun, Z. Lu, X. Chen, H. Wang, S. Mao, Y. Zhou
Journal: Annals of Oncology (2020)
692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
Authors: C. Cattrini, R. Lozano Mejorada, V. Conteduca, M. Ruiz-Vico, M.P. Lolkema, D. Lorente, S. Sandhu, N. Romero Laorden, Y. Loriot, A.A. Azad, L. Costa, A. Vinceneux, R. Kanesvaran, Y. Ürün, J. Puente, G. Attard, N. Mehra, U. De Giorgi, D. Olmos Hidalgo, E. Castro Marcos
Journal: Annals of Oncology (2020)
889MO Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group
Authors: B. Nunez Garcia, M. Rodríguez-Pertierra, S. Sequero, D. Aguiar, L. Gálvez Carvajal, A. Ruano-Ravina, J. Guma I Padro, F.R. García Arroyo, Y. Garitaonaindia, C. Quero, Z. Provencio, V. Calvo de Juan, C. González-San Segundo, M. Provencio Pulla
Journal: Annals of Oncology (2020)
Flu vaccination programme: could medical students be the answer?
Authors: Jack O Lyon
Journal: BMJ (2020)

The 2019-20 flu programme vaccinated just over 15 million people. The newly expanded programme opens up eligibility to 30 million people. In order to achieve this task, healthcare staff will need to double their efforts. This is simply not realistic.

In a year where staff have been overwhelmed by the challenge of covid-19, now asking them to deliver twice as many …
1755P The beginning of the COVID-19 era: The perception of oncological patients (pts) in active treatment at the Brindisi and Mauriziano Hospital Oncology Departments
Authors: D. Loparco, M. Di Maio, L. Orlando, F. Dascanio, C. Caliolo, G. Ignazzi, P. Schiavone, G. Lacidogna, A. Quaranta, D. Marino, G. Del Bene, F. Vignani, P. Fedele, E. Sperti, M. Caloro, S. Terzolo, M. D'Amico, A. Bellezza, R. Comite, S. Cinieri
Journal: Annals of Oncology (2020)
LBA20 Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Authors: R. Jones, A. Casbard, M. Carucci, J. Smith, K. Ingarfield, J.M.W. Gee, Z. Hudson, F. Alchami, L. Hayward, T. Hickish, D. Hwang, K. McAdam, S. Spensley, S. Waters, D. Wheatley, M. Beresford
Journal: Annals of Oncology (2020)
294P Pyrotinib and capecitabine for HER2–positive metastatic breast cancer patients with previously untreated brain metastases: A single-group multicenter phase II study
Authors: M. Yan, Q. Ouyang, T. Sun, L. Niu, J. Yang, L. LI, Y.H. Song, C. Hao
Journal: Annals of Oncology (2020)
1571P Chemotherapy in the COVID-19 era: The patient’s perception
Authors: M. Hennessy, A. Linehan, D. Cowzer, Z. Coyne, O. Fitzpatrick, R. Ní Dhonaill, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach
Journal: Annals of Oncology (2020)
1486P The impact of CT-based body composition parameters on survival outcomes in Western patients (pts) with resected gastric and gastroesophageal junction adenocarcinoma (GEA)
Authors: M. Salati, A. Pecchi, F. Prampolini, S. Kaleci, C. Santini, F. Canino, S. Benatti, A. Casadei Gardini, F. Gelsomino, P. Torricelli, G. Luppi, M. Dominici, A. Spallanzani
Journal: Annals of Oncology (2020)
1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
Authors: R. Dziadziuszko, S. Siena, D.S.W. Tan, B.C. Cho, M-J. Ahn, K. Goto, P. Garrido-Lopez, A.F. Farago, H.H.F. Loong, D. Tosi, T. John, J. Wolf, C-H. Chiu, S.V. Liu, M.R. Patel, A. Drilon, B. Pitcher, B. Simmons, R.C. Doebele
Journal: Annals of Oncology (2020)
322P Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3
Authors: H.S. Rugo, M. Cristofanilli, S. Loibl, N. Harbeck, A. DeMichele, H. Iwata, Y.H. Park, A. Brufsky, K. Puyana Theall, X. Huang, L. McRoy, E. Bananis, N.C. Turner
Journal: Annals of Oncology (2020)
1734P Do cancer patients really do worse? A study in a UK tertiary hospital within a COVID-19 epicentre
Authors: C.C.T. Sng, A. Wu, Y.N.S. Wong, G.B. Soosaipillai, D. Ottaviani, A.J.X. Lee, M. Galazi, N. Chopra, S. Benafif, H.M. Shaw
Journal: Annals of Oncology (2020)
1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Authors: S.S. Schalm, T. Dineen, S.M. Lim, C-W. Park, J. Hsieh, R. Woessner, Z. Zhang, K. Wilson, M. Eno, D. Wilson, B. Williams, J. Campbell, C. De Savi, F. Stevison, C. Utt, T. Guzi, M. Dorsch, K. Hoeflich, B.C. Chul Cho
Journal: Annals of Oncology (2020)
334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
Authors: I. Bulat, M. Maglakelidze, B. Krastev, H-T. Arkenau, C. Murias, R.D. Baird, R. Roylance, A.M. Wardley, A. Crijanovschi, M. Gogiladze, Y. Lu, A. McCullough, S. Jain, C.D. Wolfgang, R. Malik, A.P. Beelen
Journal: Annals of Oncology (2020)
Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea
Authors: Sara Op de Beeck, Andrew Wellman, Marijke Dieltjens, Kingman P. Strohl, Marc Willemen, Paul H. Van de Heyning, Johan A. Verbraecken, Olivier M. Vanderveken, Scott A. Sands
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Approximately one-third of patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) therapy are incomplete responders, despite careful patient selection based on baseline characteristics and drug-induced sleep endoscopy.Objectives: Here we use polysomnographic endotyping to assess the pathophysiological mechanisms underlying favorable versus incomplete responses to HGNS therapy.Methods: Baseline polysomnography data of the STAR (Stimulation Therapy for Apnea Reduction) trial were included. Raw baseline polysomnographic data from 91/126 patients were available for analysis. Traits-loop gain, arousal threshold, collapsibility, and muscle compensation-were calculated from the baseline polysomnography data according to Sands and colleagues (AJRCCM 2018, SLEEP 2018). Logistic regression assessed apnea-hypopnea index (AHI)-adjusted associations between HGNS response (>50% reduction in AHI to <10/h at 1 yr) and OSA traits.Measurements and Main Results: Overall, HGNS treatment reduced AHI from 30.7 (24.9-39.9) to 8.5 (4.0-19.5) events/h (P < 0.0001; median [quartiles 1-3]); N = 53/91 were responders. In adjusted analysis, a favorable response to therapy was independently associated with higher arousal threshold (odds ratio [95% confidence interval]: 6.76 [2.44-23.3], P = 0.001), greater compensation (odds ratio: 4.22 [1.70-12.55] per SD, P = 0.004), and lower loop gain (in milder collapsibility, per significant interaction, P = 0.003). The higher arousal threshold was evident in responders before adjusted analysis. Predicted responders had an approximately fourfold lower treatment AHI versus predicted nonresponders (4.9 [2.7-8.5] vs. 20.7 [10.9-29.7], P < 0.0001; median [quartiles 1-3]); differences remained significant after cross-validation.Conclusions: Favorable responses to HGNS therapy are associated with the pathophysiological traits causing OSA, particularly a higher arousal threshold. Along with established criteria, individuals with favorable traits could potentially be prioritized for precision HGNS therapy.This analysis was a secondary analysis of the STAR trial registered with clinicaltrials.gov (NCT01161420).
Hepatocyte Mitogen‐Activated Protein Kinase Kinase 7 Contributes to Restoration of the Liver Parenchyma Following Injury in Mice
Authors: Takako Ooshio, Masahiro Yamamoto, Kiyonaga Fujii, Bing Xin, Kenji Watanabe, Masanori Goto, Yoko Okada, Akira Suzuki, Josef M. Penninger, Hiroshi Nishina, Yuji Nishikawa
Journal: Hepatology (2020)

Background and Aims Mitogen‐activated protein kinase kinase (MKK) 7 and MKK4 are upstream activators of c‐Jun NH 2 ‐terminal kinases (JNKs) and have been shown to be required for the early development of the liver. Although it has been suggested that MKK7 might be involved in the regulation of hepatocyte proliferation, the functional role of MKK7 in the liver has remained unclear. Approach and Results Here, we examined phenotypic alterations in liver‐specific or hepatocyte/hematopoietic cell–specific MKK7 knockout (KO) mice, which were generated by crossing MKK7 LoxP/LoxP with albumin–cyclization recombination (Alb‐Cre) or myxovirus resistance protein 1–Cre mice, respectively. The livers of Alb‐Cre −/+ MKK7 LoxP/LoxP mice developed without discernible tissue disorganization. MKK7 KO mice responded normally to liver injuries incurred by partial hepatectomy or injection of CCl 4 . However, tissue repair following CCl 4 ‐induced injury was delayed in MKK7 KO mice compared with that of control mice. Furthermore, after repeated injections of CCl 4 for 8 weeks, the liver in MKK7 KO mice showed intense fibrosis with increased protractive hepatocyte proliferation, suggesting that MKK7 deficiency might affect regenerative responses of hepatocytes in the altered tissue microenvironment. MKK7 KO hepatocytes demonstrated normal proliferative activity when cultured in monolayers. However, MKK7 KO significantly suppressed branching morphogenesis of hepatocyte aggregates within a collagen gel matrix. Microarray analyses revealed that suppression of branching morphogenesis in MKK7 KO hepatocytes was associated with a reduction in mRNA expression of transgelin, glioma pathogenesis related 2, and plasminogen activator urokinase‐type ( Plau ); and forced expression of these genes in MKK7 KO hepatocytes partially recovered the attenuated morphogenesis. Furthermore, hepatocyte‐specific overexpression of Plau rescued the impaired tissue repair of MKK7 KO mice following CCl 4 ‐induced injury. Conclusions MKK7 is dispensable for the regenerative proliferation of hepatocytes but plays important roles in repair processes following parenchymal destruction, possibly through modulation of hepatocyte–extracellular matrix interactions.
612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
Authors: R. Lozano Mejorada, E. Castro Marcos, I.M. Aragon, H. Thorne, F. Lopez Campos, A. Sanz, C. Alonso, U. Anido, M.J. Juan Fita, A.M. Gutierrez Pecharromán, M. Ramirez-Backhaus, J. Balmana, I. Chirivella Gonzalez, G. Llort, N. Romero Laorden, S. Arevalo Lobera, J. Rubio Briones, C.C. Pritchard, S. Sandhu, D. Olmos Hidalgo
Journal: Annals of Oncology (2020)
1561P Anemia and iron deficiency (ID) in association with tissue iron regulators - Hepcidin, ferroportin and ZIP14 expression in patients with pancreatic cancer (PC)
Authors: M. Osmola, A. Waszczuk-Gajda, B. Gierej, L. Kraj, K. Wozniak, B. Ziarkiewicz-Wróblewska, G.W. Basak
Journal: Annals of Oncology (2020)
1534P Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan
Authors: L. Abushahin, P. Cockrum, A. Surinach, B. Belanger
Journal: Annals of Oncology (2020)
1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
Authors: C. Haymaker, R.H.I. Andtbacka, D.B. Johnson, M.F. Shaheen, S. Rahimian, S. Chunduru, N. Gabrail, G. Doolittle, I. Puzanov, J. Markowitz, C. Bernatchez, A. Diab
Journal: Annals of Oncology (2020)
930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head &amp; neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
Authors: H. Carinato, M. Burgy, C. Fischbach, M. Kalish-Weindling, L. Pabst, V. Frasie, A. Thiery, P. Coliat, M.F. Demarchi, T. Petit, C. Borel
Journal: Annals of Oncology (2020)
Erratum. Longitudinal Study of Depressive Symptoms and Progression of Insulin Resistance in Youth at Risk for Adult Obesity. Diabetes Care 2011;34:2458–2463
Authors: Lauren B. Shomaker, Marian Tanofsky-Kraff, Elizabeth A. Stern, Rachel Miller, Jaclyn M. Zocca, Sara E. Field, Susan Z. Yanovski, Van S. Hubbard, Jack A. Yanovski
Journal: Diabetes Care (2020)

In Table 1 of the above-referenced article, the type of data presented was misidentified in the legend. …
1299P Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT)
Authors: A. Addeo, M.J. Hochmair, U. Janzic, E. Dudnik, A. Charpidou, A. Pluzanski, T-E. Ciuleanu, I. Shterev Donev, J. Elbaz, R. Lupu, R.G. Ott, N. Peled
Journal: Annals of Oncology (2020)
1550P Combination therapy of low molecular weight heparins, chemotherapy and immunotherapy induce antitumor activity in pancreatic cancer
Authors: M.V. Karamouzis, P. Sarantis, E. Koustas, A. Papadimitropoulou, P. Papakotoulas, A. Bokas, D. Schizas, A. Papalampros, E. Felekouras, T. Liakakos, A.G. Papavassiliou
Journal: Annals of Oncology (2020)